• A
  • A
Font Size

Sign Up

Sign up for more information

Get the latest materials and communications about EYLEA – and a complimentary pocket magnifier, too.

This offer is valid while supplies last. All fields are required unless otherwise indicated.

I am a...

{{i.Text}}
Text
Please choose one

My loved one's current diagnosis is...

{{d.Text}}
Please choose one
Please enter your first name
Please enter your last name
Please enter your address
Please enter your city
{{item.FullName}}
Please enter your state
Please enter your state
Please enter a valid ZIP code
Please enter a valid ZIP code
Please enter a valid email address
Please enter a valid email address
Email isn't unique
Please enter a valid phone number.
(ex: 888-888-8888)
Enter a date of birth in this format: mm/dd/yy
Please enter a valid birthdate

I authorize Regeneron Pharmaceuticals, Inc., the maker of EYLEA® (aflibercept) Injection, together with its collaborators, affiliates, representatives, agents, and contractors (collectively, "Regeneron"), to provide me with educational and promotional information, materials, and services. Regeneron may de-identify any health information I provide and use it in performing research, education, business analytics, marketing studies, or for other commercial purposes. Additionally, I understand that Regeneron may use my information (1) to help improve, develop, and evaluate products, services, materials, and programs related to my condition and treatment; and (2) as otherwise described in the Regeneron Privacy Policy.

I also agree that Regeneron may contact me by mail or e-mail with information about EYLEA, including its FDA-approved indications, diseases, treatments and any related information, which may contain personal information. Message and data rates may apply. I understand that I may opt out of these communications by e-mailing commercialanalytics@regeneron.com or by sending a letter to Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, Attention: Commercial Analytics.

By clicking "I accept" below, I am signing this form, indicating that I am at least 18 years old, and confirming that I have read, understand, and agree with the Regeneron Privacy Policy and Terms and Conditions.

By checking this box and clicking "I accept" below, I further authorize Regeneron to contact me by phone or SMS/text message at the telephone number I have provided, which could result in messaging or data charges to me depending on my wireless service plan. I agree to notify Regeneron if my number changes in the future. I also authorize Regeneron to contact me using prerecorded/artificial voice messages or an automatic dialing system. I understand that these calls or messages may advertise or market Regeneron's products, goods, or services. I do not need to agree to receive calls or SMS/text messages as a condition of purchasing any goods or services.
I accept
Please select.
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with theuse of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.